Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Neoplasms 1Neoplasm Metastasis 1Head and Neck Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × LY3295668 erbumine × Clear all
NCT03092934 2021-07-02

A Study of AK-01 (LY3295668) in Solid Tumors

Eli Lilly and Company

Phase 1/2 Completed
13 enrolled 17 charts
BreastHead & NeckThoracic

Breast Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡